Zomedica Corp. · OTC:ZOMDF
Zomedica — HC Wainwright Bioconnect Conference 2023
30 slides from Zomedica's conference presentation, May 2, 2023
Slide 1: Larry Heaton, Chief Executive Officer, June 2023
Larry Heaton Chief Executive Officer June 2023 6/12/2023 1
Slide 2: Forward Looking Statements
Forward Looking Statements These materials have been prepared for informational purposes only in relation to Zomedica and are not, under any circumstances, to be construed as an offering of any securities for sale directly or indirectly in any province or territory of Canada, in the United States or
Slide 3: Investment Highlights
Investment Highlights Attractive Industry: Humanization of pets drives recession resistant market growth. Differentiated Solutions: Innovative technology to improve care, practice workflow & customer economics Experienced Management Team: Start-up mentality focused on flawless execution Manufacturin
Slide 4: Global Veterinary Services Market Valued at $97.3 Billion in 2020
GLOBAL VETERINARY SERVICES MARKET VALUED AT $97.3 BILLION IN 2020* Veterinary services in the US are projected to surpass $62.2 billion in $62.2B 2023.** Therapeutic devices and point of care diagnostics are a key part of the Vet Services segment. SOURCE: * Grandview Research Veterinary Services Mar
Slide 5: The Pandemic Sparked a Wave of Pet Adoptions in the US
THE PANDEMIC SPARKED A WAVE OF PET ADOPTIONS IN THE US MORE THAN 23 MILLION AMERICAN HOUSEHOLDS ADOPTED A PET DURING THE PANDEMIC.1 Percentage of US Dog-Owning Households with 1 or more Dogs Under 2 Years Old2 (as of December 2021) 27% 27% 19% 6 months to 2years 12% 13% 6% 6% 1% Less than 6 months G
Slide 6: For Pet Owners, Their Pets Are Part of the Family
FOR PET OWNERS, THEIR PETS ARE NO LONGER JUST COMPANIONS… THEY’RE PART OF THE FAMILY The percentage of pet owners that “agree” or “strongly agree” with the following statements: 95% “My pet is part of my family” 92% “Nothing would ever convince me to give up my pet” SOURCE: The Human Animal Bond Ins
Slide 7: Challenges our Customers Face
Challenges our Customers face- “It’s Never Been Harder To Practice Veterinary Medicine Labor, both DVM and staff are a critical issue causing While pharmacy revenue remains important Veterinarians to work more than ever. Vet practices are losing out to online retail on critical chronic refills and p
Slide 8: Zomedica Mission & Vision
Zomedica Mission & Vision Zomedica is bringing innovative PulseVet® Shock Wave System diagnostic and therapeutic technology to Veterinarians to Assisi LOOP ® improve the quality of care for the pet, the satisfaction of the pet parent, and the workflow, cash flow and profitability of the practice. Ve
Slide 9: Veteran Management Team with Decades of Experience
Veteran Management Team with Decades of Experience Tony Blair Greg Blair Larry Heaton Peter Donato EVP & COO VP BD & Strategic Planning CEO EVP & CFO 35+ Years of 30+ Years of 30+ Years of 30+ Years of Experience Experience Experience Experience Bill Campbell Adrian Lock Nicole Westfall VP Imaging S
Slide 10: Zomedica Growth by Acquisition
Zomedica Growth by Acquisition Total Annual Cumulative Y/Y Deal Date Type Cost Addressable Annual Growth Market (TAM) TAM (thru 12/31/23) TRUFORMA® March 2021 Launch $775M $0.78B +300% Stock PulseVet® October 2021 $71M $150M $0.93B +31% acquisition Convertible Launched VetGuardian™ May 2022 $2.75M $
Slide 11: US Total Addressable Market
US Total Addressable Market 30,000 Total Addressable Market: Total Addressable Market: Small Animal U.S. Annual Recurring Revenue & U.S. Capital Revenue 4,450 Equine or Mixed PulseVet Practices(2) $150M PulseVet $1B TRUFORMA TRUVIEW $775M $1.3B VetGuardian $450M $2.5B $1.3B Assisi Vet Guardian $210M
Slide 12: Omnichannel Sales Strategy
Omnichannel Sales Strategy Field Sales Reps Email Marketing Inside Sales Reps Public Relations Professional Services Veterinarians Custom Marketing and SEO Event and Conference Sales Web and Social Media International Sales Distributers Print and Catalog Ads Unified Multi-Channel Marketing Ecommerce
Slide 13: Current Global Sales Footprint
Current Global Sales Footprint UXR GroVet (UK, Belgium, Luxembourg, Denmark, Western Drug Distribution Center Sweden, Norway) Holistic Veterinary Solutions (Canada) Companion Consultancy Zomedica (UK) KFDA (Switzerland ) (South Korea) DAME IC VE DIS TIC LTD STI MWI Veterinary Supply Co. (Turkey) Cov
Slide 14: Expanding Product Portfolio
Expanding Product Portfolio PulseVet® Shock Wave System Clinically Proven Global Leader TRUFORMA® Reference Lab Accuracy with Drive assay utilization Point of Care Convenience Expand Equine Indications for Launch into small use to grow utilization Expand installed base animal market Expand assay off
Slide 15: myZomedica Experience
myZomedica.com • Plug and play IoT experience. No clinic networking required. myZomedica Experience • View test results remotely from any internet connected desktop, laptop, or tablet. • Rules based test result views anticipating clinician needs for interpretation. • Online repository of useful devi
Slide 16: Zomedica Revenue Up 46% 1Q22 to 1Q23
Zomedica Revenue Up 46% 1Q22 to 1Q23 All Figures Are Dollars In Thousands Total Revenue(1) Qorvo and VetGuardian 7,000 Agreements PulseVet, Revo, and Assisi Deals Closed 6,157 6,000 5,482 5,000 4,776 4,081 4,246 4,000 3,751 3,000 2,000 TRUFORMA Launch 1,000 14 16 23 0 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3
Slide 17: Driven Organically, Through M&A, and Across Segments
Driven Organically, Through M&A, and Across Segments All Figures Are Dollars In Thousands Organic Revenue(1) Acquired Revenue(2) 6,000 1,500 1,322 Y/Y: +11% 5,096 Y/Y: -- 5,000 4,246 4,081 3,765 4,160 1,011 1,061 4,000 3,751 1,000 3,000 2,000 500 1,000 14 16 23 0 0 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22
Slide 18: Product Line Overview
Product Line Overview 6/12/2023 18
Slide 19: TRUFORMA – Reference Lab Accuracy at the Point of Care
TRUFORMA® – Reference Lab Accuracy at the Point of Care • Based on clinically proven, highly sensitive Bulk Acoustic Wave (BAW) technology Adrenal & Thyroid Point of Care • Developed and commercialized by Qorvo in Telecom & Aerospace industries Panels for Dogs and Cats • FDA emergency use authorizat
Slide 20: TRUFORMA Assay Development Targets
TRUFORMA® Assay Development Targets On the Market In Development Potential Opportunities Adrenal & Thyroid Panel for Dogs Expanding into high value Point Becoming a broad-based Point and Cats of Care solutions of Care lab solution 6 Now Available Adrenal & Thyroid Potential Targets cTSH NT ProBNP (c
Slide 21: Revo2 Asset Acquisition - An innovative veterinary imaging company
Revo2 Asset Acquisition - An innovative veterinary imaging company TRUVIEW Digital Microscopy w/fully automated slide preparation • Innovative digital imaging system with best-in-class visualization • First in class automated slide preparation Zomedica TRUVIEW system • Improves workflow in the clini
Slide 22: Zomedica & VetGuardian Wireless Monitoring
Zomedica & VetGuardian ® Wireless Monitoring Convertible Note Investment with Anticipated Next Steps • Note provides funding for current management to complete development • Collaboration on final design, cloud integration with myZomedica & manufacturing • Zomedica began commercialization January 20
Slide 23: PulseVet - Global Leader in Shock Wave Therapy
PulseVet - Global Leader in Shock Wave Therapy • Global leader in shock wave therapy for wound healing, and difficult to treat injuries • 14 Published clinical studies, including randomized control trials • FDA cleared for human indications • 20 small animal applications; 40 equine applications • Ra
Slide 24: PulseVet – What the Vet sees – Seeing is Believing!
PulseVet® – What the Vet sees – Seeing is Believing! BEFORE QUICK AFTER P U L S E V E T T R E AT M E N T CLINIC VISIT P U L S E V E T T R E AT M E N T 24
Slide 25: Acquired Capabilities: Assisi Product Line
Assisi Product Line – Complements PulseVet® with in home supplemental treatment Assisi Loop® & Loop Lounge • Sold for pain and inflammation from OA and wound healing • "Re-sposable" requiring replacement after 150 treatments Newly Launched Line Extensions • Dental loop indicated for gum disease and
Slide 26: Sniffing out Future Technologies
Sniffing out Future Technologies
Slide 27: Business Development Opportunities
Business Development Opportunities Adding to Strong Product Portfolio Accelerating Balance Sheet • PulseVet shock wave therapy Innovation • $147.5 million in liquidity as • VetGuardian wireless • Industry innovation accelerating of 3/31/23 remote monitoring but commercialization is difficult and cap
Slide 28: Financial Foundation & Performance
Financial Foundation & Performance 2023 Balance Sheet as of March 31, 2023 ($ 000's) 2023 Q1 Profit & Loss Statement Cash and Cash Equivalents 8,353 Revenue 5,482 Available-for-sale Securities (Current) 112,698 Cost of Revenue 1,647 Available-for-sale Securities (Non-Current) 26,409 Gross Profit 3,8
Slide 29: Why Invest In Zomedica?
Why Invest In Zomedica? Veteran management team Significant Revenue Growth - TRUFORMA: 300% vs. 2021 Track record, leadership & leading revenue growth and - PulseVet: 31% vs. 2021 capital to continue acquisitions driving to profitability in large, thru 3Q2022 of complementary products to growing, re
Slide 30: Appendix Endnotes
Appendix Endnotes • (1) JP Morgan coverage initiation report on Idexx and Heska, January 2021 • (2) JP Morgan AH Industry overview Jan 2021 • (3) Credit Suisse Animal Health Industry Primer, June 2021 Pg 16 • Grandview Research August 2021 • Global Market Insights • 2016 pet owner survey conducted b